论文部分内容阅读
虽然在过去的几十年里卵巢癌的标准治疗得到了明显的改进,但细胞毒性化疗耐药问题导致了仍有较多女性死于卵巢癌。通过对卵巢癌生物性质的了解使人们在癌细胞中发现存在较多有潜力的分子靶点,并针对这些靶点提出了作用于细胞不同于传统化疗药位点的新颖因子。这些因子现正进行临床实验,以确定其应用价值,且已经显示了令人惊喜的抗肿瘤活性。在本文中,通过关注在卵巢癌生长过程中不可缺少的血管生成分子基础,了解其中常用的靶点治疗及其临床应用。
Although the standard treatment of ovarian cancer has been significantly improved over the past decades, the problem of resistance to cytotoxic chemotherapy has led to the death of more women than ovarian cancer. By understanding the biological properties of ovarian cancer, many potential molecular targets have been found in cancer cells, and for these targets, novel factors that act on cells different from traditional chemotherapeutic agents have been proposed. These factors are now undergoing clinical trials to determine their value and have shown surprising antitumor activity. In this article, we focus on the molecular basis of angiogenesis in the process of ovarian cancer growth and understand the commonly used target therapy and its clinical application.